Parkinson's drug safety trial halted early
NCT ID NCT04976127
First seen Apr 25, 2026 · Last updated May 03, 2026 · Updated 3 times
Summary
This early-stage study tested the safety of an intravenous drug called talineuren in 22 people with Parkinson's disease. Talineuren is a form of GM1, a natural substance, given as an add-on to their usual treatment. The study was stopped early, and its main goal was to check for side effects, not to prove the drug works.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PARKINSON DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Neurologisches Institut Konolfingen
Konolfingen, Canton of Bern, 3510, Switzerland
Conditions
Explore the condition pages connected to this study.